Literature DB >> 23567160

Atypical incomplete femoral fractures in asymptomatic patients on long term bisphosphonate therapy.

M B Allison1, L Markman, Z Rosenberg, R L Vieira, J Babb, N Tejwani, V Peck.   

Abstract

OBJECTIVES: Progression of an incomplete atypical femoral fracture (IF) to a complete fracture in patients on long term bisphosphonate (BP) therapy can be catastrophic. We aimed to determine the frequency and imaging features of IF in asymptomatic patients on long-term BP therapy and to identify distinguishing clinical and laboratory markers in the subset of patients who develop these fractures.
MATERIAL AND METHODS: From August 2009 to March 2011, 220 femoral radiographs in 110 asymptomatic patients (101 women, 9 men, age 47-94) were reviewed by 2 radiologists. All patients were on BP therapy for at least 3 years and had no history of hip/thigh pain or recent trauma. MRI was performed when a fracture was suspected on radiographs. Bone mineral density, serum calcium, 25-hydroxy vitamin D, intact parathyroid hormone, serum c-telopeptide and urine n-telopeptide were obtained in all patients.
RESULTS: Two of 110 patients (1.82%, confidence interval of 0.6% to 6.3%) had 3 IFs. Both patients, age 50 and 57, were Caucasian, active and on BP for 8 years. MRI confirmed radiographic findings in both patients. Both women had T-scores in the osteopenic range at 2 sites and osteoporotic range at 1 site.
CONCLUSION: The 1.82% frequency of IF in asymptomatic patients on long term BP therapy is higher than that suggested in the literature. Statistical differences between fracture and non-fracture groups were not presented as the patient population was too small to draw any significant conclusions.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23567160     DOI: 10.1016/j.bone.2013.03.018

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  6 in total

Review 1.  Review: epidemiology and pathophysiology of atypical femur fractures.

Authors:  Alvin C Ng; Meng Ai Png; David T Chua; Joyce S B Koh; Tet Sen Howe
Journal:  Curr Osteoporos Rep       Date:  2014-03       Impact factor: 5.096

2.  Absence of femoral cortical thickening in long-term bisphosphonate users: implications for atypical femur fractures.

Authors:  Foster Chen; Zhong Wang; Timothy Bhattacharyya
Journal:  Bone       Date:  2014-01-25       Impact factor: 4.398

Review 3.  Stress fractures: pathophysiology, clinical presentation, imaging features, and treatment options.

Authors:  George R Matcuk; Scott R Mahanty; Matthew R Skalski; Dakshesh B Patel; Eric A White; Christopher J Gottsegen
Journal:  Emerg Radiol       Date:  2016-03-22

Review 4.  Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years?

Authors:  Xiao-Long Xu; Wen-Long Gou; Ai-Yuan Wang; Yu Wang; Quan-Yi Guo; Qiang Lu; Shi-Bi Lu; Jiang Peng
Journal:  J Transl Med       Date:  2013-12-11       Impact factor: 5.531

5.  Identifying Incomplete Atypical Femoral Fractures With Single-Energy Absorptiometry: Declining Prevalence.

Authors:  Malachi J McKenna; Fergus E McKiernan; Bernie McGowan; Carmel Silke; Kathleen Bennett; Susan van der Kamp; Paul Ward; Conor Hurson; Eric Heffernan
Journal:  J Endocr Soc       Date:  2017-02-13

6.  Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea.

Authors:  Young Kyun Lee; Soyeon Ahn; Kyoung Min Kim; Chang Suk Suh; Kyung Hoi Koo
Journal:  J Korean Med Sci       Date:  2018-01-29       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.